Titlebook: STAT Inhibitors in Cancer; Alister C. Ward Book 2016 Springer International Publishing Switzerland 2016 Alternate inhibitors.Cancer Etiolo

EXCEL

过滤

STAT Proteins in Cancer,sponse to, and mediate signaling downstream of, growth factors and cytokines. STATs are dysregulated in a broad range of cancer types. Although the genes that encode STATs are rarely mutated in cancer, constitutive phosphorylation and hence activation of STATs, particularly STAT3, is a common altera

大都市

Archipelago

Historical Development of STAT3 Inhibitors and Early Results in Clinical Trials,ancers has been firmly established. Detailed understanding of how STAT3 activity is tightly regulated by the balance between activating and inhibitory circuits provides important insights of how STAT3 becomes deregulated in cancer cells. A large number of STAT3 inhibitors have been developed. The pr

虚情假意

STAT3 Inhibitors in Cancer: A Comprehensive Update,s in response to peptide hormone binding. It is known to play a prominent role in the initiation and progression of cancer, as it is constitutively activated in 25–100 % of more than 25 different malignancies and has been implicated in nearly all the hallmarks of cancer. In addition, STAT3 contribut

seduce

Targeting Upstream Janus Kinases,ing normal development and homeostasis. The JAKs also make a major contribution to the hyperactivation of STATs observed in various malignancies, including through mutation of the JAKs themselves in several neoplastic conditions. These properties have made JAKs attractive targets for the development

哀求

Inhibitors of Upstream Inducers of STAT Activation,tream signaling molecules responsible for STAT activation have been identified. Many of these proteins are able to be targeted with specific antibodies or small molecules and so represent attractive candidates for therapeutic development. This chapter details several promising agents that target rec

潜移默化

Expediency

STAT3 Inhibitors in Cancer: A Comprehensive Update, an even more attractive target for cancer therapy. In this chapter, we give an overview of strategies involved in targeting STAT3 and discuss recent advances in the development of STAT3 modulating agents.

场所